Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2007

View Archived Issues

PTP-1B inhibitors claimed in recent patent by Metabasis

Several series of protein kinase inhibitors claimed for the treatment of cancer

Eisai announces first quarter results

Curcumin reverses amyloid pathology in mouse model of Alzheimer's disease

Cholesterol biosynthesis inhibitor reduces amyloid-beta in vitro

Denufosol improves lung function in phase II cystic fibrosis study

First half 2007 results reported by sanofi-aventis

Urigen begins phase II study of URG-101 for PBS

Allos begins enrollment for phase I study of PDX with vitamin B12 and folic acid

CombinatoRx begins phase IIa study of CRx-401 for type 2 diabetes

Millennium begins phase II trial of Velcade for MM

Positive results for Neuraxon's phase I trial of NXN-188 for migraine

Accentia reports interim analysis of phase III trial of SinuNase for CS

GSK begins phase I trial of GSK-923295 for solid tumors

VGX begins IND-enabling preclinical toxicology studies of three product candidates

EKR acquires marketing rights to Pacira's DepoDur for postoperative pain

New recombinant neuregulin-1 ameliorates cardiac output in chronic heart failure

Noven acquisition of JDS Pharmaceuticals completed

Parion and Gilead to codevelop ENaC inhibitors for pulmonary diseases

Vion enrolls 85 elderly patients in pivotal phase II trial of Cloretazine for AML

European Commission grants Chelsea Therapeutics' droxidopa two orphan drug titles

EMEA recommends orphan drug status for Progen's PI-88 as it enters phase III trial

The MMRC and Proteolix start carfilzomib phase II clinical trial in multiple myeloma

Oncoscience completes enrollment in phase III brain cancer trial of nimotuzumab

Hedgehog signaling activators discovered with potential in neurodegenerative disorders

Novel, potent hydroxyhydantoin MMP inhibitors presented at ACS meeting

FDA approves Novartis' once-yearly Reclast for postmenopausal osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.